Roundhill GLP-1 & Weight Loss ETF — Fact Sheet (June 2024)

3 slides from Roundhill GLP-1 & Weight Loss ETF's fact sheet, June 2024

Slide 1: OZEM: Obesity Epidemic, Revolutionary Drugs, Market Growth
OZEM Obesity Epidemic: Global obesity rates have nearly tripled since 1975 and are projected to impact over half the population by 20351! Revolutionary Drugs: Groundbreaking GLP-1 treatments, such as Ozempic, Wegovy, and Zepbound, are leading medical advancements in weight management.? Market Growth
Slide 2: GICS Sub Industry and Market Capitalization Breakdown
OZEM GICS Sub Industry Breakdown Market Capitalization Breakdown — Pharmaceuticals 66.4% Large Cap ($108) 60.8% Biotechnology 30.9% . Life Sciences Tools & 16% Mid Cap ($2-10B) 24.4% Services ° Small Cap (<$2B) 14.4% Health Care Services 0.8% — — OZEM Performance (as of 5/21/24) Since Inception (05/
Slide 3: Investment risks and prospectus disclosure
O Investors should consider the investment objectives, risk, charges and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about Roundhill ETFs please call 1-855-561-5728 or visit the website at www.roundhillinvestments.com/etf/OZEM. Read the